These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25207666)

  • 21. Drug-drug interaction between clopidogrel and the proton pump inhibitors.
    Norgard NB; Mathews KD; Wall GC
    Ann Pharmacother; 2009 Jul; 43(7):1266-74. PubMed ID: 19470853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proton pump inhibitor-induced rhabdomyolysis and hyponatremic delirium.
    Bebarta VS; King JA; McDonough M
    Am J Emerg Med; 2008 May; 26(4):519.e1-2. PubMed ID: 18410837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
    Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proton pump inhibitor-induced acute interstitial nephritis.
    Härmark L; van der Wiel HE; de Groot MC; van Grootheest AC
    Br J Clin Pharmacol; 2007 Dec; 64(6):819-23. PubMed ID: 17635502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
    Leonard CE; Bilker WB; Brensinger CM; Flockhart DA; Freeman CP; Kasner SE; Kimmel SE; Hennessy S
    Stroke; 2015 Mar; 46(3):722-31. PubMed ID: 25657176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous reactions to proton pump inhibitors: a case-control study.
    Chularojanamontri L; Jiamton S; Manapajon A; Suvanasuthi S; Kulthanan K; Dhana N; Jongjarearnprasert K
    J Drugs Dermatol; 2012 Oct; 11(10):e43-7. PubMed ID: 23134998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors.
    Almebayadh M; Regnier-Rosencher E; Carlotti A; Goulvestre C; Le Guern V; Mouthon L; Avril MF; Dupin N
    Dermatology; 2013; 226(2):119-23. PubMed ID: 23548825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pantoprazole-Associated Thrombocytopenia: A Literature Review and Case Report.
    Phan AT; Tseng AW; Choudhery MW; Makar JB; Nguyen C; Farmand F
    Cureus; 2022 Feb; 14(2):e22326. PubMed ID: 35371663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lessons from two cases of anaphylaxis to proton pump inhibitors.
    Choi SW; Han JM; Bae YJ; Lee YS; Cho YS; Moon HB; Kim TB
    J Clin Pharm Ther; 2012 Oct; 37(5):614-6. PubMed ID: 22642701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us?
    Luk CP; Parsons R; Lee YP; Hughes JD
    Ann Pharmacother; 2013 Jun; 47(6):773-80. PubMed ID: 23632281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Case of Pantoprazole Anaphylaxis with Cross Reactivity to All Proton Pump Inhibitors: Finding a Safe Alternative.
    Turedi O; Sozener ZC; Kendirlinan R; Bavbek S
    Curr Drug Saf; 2017; 12(3):198-200. PubMed ID: 28699491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
    Yaghoobi M; Padol S; Yuan Y; Hunt RH
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):583-90. PubMed ID: 20061959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of cytopenia in geriatric inpatients.
    Röhrig G; Becker I; Pappas K; Polidori MC; Schulz RJ
    Z Gerontol Geriatr; 2018 Feb; 51(2):231-236. PubMed ID: 28660533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nine cases of omeprazole allergy: cross-reactivity between proton pump inhibitors.
    Lobera T; Navarro B; Del Pozo MD; González I; Blasco A; Escudero R; Venturini M; Alarcón E
    J Investig Allergol Clin Immunol; 2009; 19(1):57-60. PubMed ID: 19274931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prevalence of pantoprozole associated thrombocytopenia in a community hospital.
    Dotan E; Katz R; Bratcher J; Wasserman C; Liebman M; Panagopoulos G; Spaccavento C
    Expert Opin Pharmacother; 2007 Sep; 8(13):2025-8. PubMed ID: 17714057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation and management of hypersensitivity to proton pump inhibitors.
    Bose S; Guyer A; Long A; Banerji A
    Ann Allergy Asthma Immunol; 2013 Dec; 111(6):452-7. PubMed ID: 24267357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
    Tran M; Tafreshi J; Pai RG
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):326-37. PubMed ID: 20938037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
    Hsiao FY; Mullins CD; Wen YW; Huang WF; Chen PF; Tsai YW
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1043-9. PubMed ID: 21823195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship among proton pump inhibitors, bone disease and fracture.
    Targownik LE; Leslie WD
    Expert Opin Drug Saf; 2011 Nov; 10(6):901-12. PubMed ID: 21599546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.